A share price of Stoke Therapeutics Inc [STOK] is currently trading at $19.37, up 2.65%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The STOK shares have gain 4.76% over the last week, with a monthly amount glided 51.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Stoke Therapeutics Inc [NASDAQ: STOK] stock has seen the most recent analyst activity on July 18, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $30. Previously, Chardan Capital Markets started tracking the stock with Buy rating on December 20, 2024, and set its price target to $24. TD Cowen upgraded its rating to a Outperform. TD Cowen downgraded its rating to Market Perform for this stock on July 25, 2023. In a note dated May 01, 2023, BofA Securities upgraded a Neutral rating on this stock and boosted its target price from $9 to $12.
Stoke Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.35 and $19.91. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $19.37 at the most recent close of the market. An investor can expect a potential return of 44.55% based on the average STOK price forecast.
Analyzing the STOK fundamentals
Trailing Twelve Months sales for Stoke Therapeutics Inc [NASDAQ:STOK] were 199.89M which represents 186.01% growth. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.18 and Total Capital is 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.36 points at the first support level, and at 17.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.02, and for the 2nd resistance point, it is at 20.66.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Stoke Therapeutics Inc [NASDAQ:STOK] is 6.98. Also, the Quick Ratio is 6.98, while the Cash Ratio stands at 2.62. Considering the valuation of this stock, the price to sales ratio is 5.31, the price to book ratio is 3.16 and price to earnings (TTM) ratio is 22.92.
Transactions by insiders
Recent insider trading involved Ticho Barry, CHIEF MEDICAL OFFICER, that happened on Aug 18 ’25 when 2805.0 shares were sold. Director, Kaye Edward M. MD completed a deal on Aug 18 ’25 to sell 12126.0 shares. Meanwhile, GENERAL COUNSEL & CORP SEC Allan Jonathan sold 1683.0 shares on Aug 18 ’25.
